News Releases - Research & Development News | Merck Newsroom Home

News Releases - Research & Development News

Merck Statement on FDA Advisory Committee Meeting for Suvorexant
5/22/13 6:28 pm EDT
Merck Announces FDA Acceptance of Biologics License Application for Investigational Ragweed Pollen Sublingual Allergy Immunotherapy Tablet
5/8/13 8:30 am EDT
FDA Approves Merck’s LIPTRUZET™ (ezetimibe and atorvastatin), a New Product That Can Help Powerfully Lower LDL Cholesterol
5/3/13 3:06 pm EDT
Merck & Co., Inc. and Pfizer Enter Worldwide Collaboration Agreement to Develop and Commercialize Ertugliflozin, an Investigational Medicine for Type 2 Diabetes
4/29/13 7:30 am EDT
Merck Announces Breakthrough Therapy Designation for Lambrolizumab an Investigational Antibody Therapy for Advanced Melanoma
4/24/13 7:30 am EDT
Merck to Present Updated Interim Data from Phase II Trial Evaluating Investigational NS3/4A Protease Inhibitor MK-5172 for Chronic Hepatitis C Virus Genotype 1 Infection at the International Liver Congress™
4/23/13 6:39 am EDT
Merck Enters Agreement with Bristol-Myers Squibb to Conduct a Phase II Clinical Trial Evaluating Combination of Investigational Oral Candidates MK-5172 and Daclatasvir for Chronic Hepatitis C
4/22/13 7:30 am EDT
Merck Announces FDA Acceptance of Biologics License Application for Investigational Grass Pollen Allergy Immunotherapy Tablet
3/27/13 8:00 am EDT
Merck and Luminex Corporation Enter Agreement to Develop Companion Diagnostic to Support Investigational BACE inhibitor Clinical Development Program for Alzheimer’s Disease
3/13/13 8:30 am EDT
Merck Provides Update on IMPROVE-IT Trial
3/12/13 8:00 am EDT

RSS

Patients & Caregivers
Healthcare Professionals
- EngageZone
- The Merck Manual
- Merck Medicus
- Authorized Distributors
- Clinical Trials
- Supplier Diversity
Media & Investors
Job Seekers
Company Statements

Copyright © 2009- Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved.
Privacy
Terms of Use
Site Map

Business Wire NewsHQ℠